Celltrion has launched three additional biosimilars in Brazil, expanding its local product lineup to ten. The company aims to leverage its existing sales network and market share to facilitate the early adoption of these new products and strengthen its foothold in the Latin American market.
On November 5, Celltrion announced that its Brazilian subsidiary released the autoimmune disease treatment 'Coivolma' (active ingredient: ustekinumab) and the bone disease treatment 'Stoboclo' and 'Osenbelt' (active ingredient: denosumab) last month.
The newly launched products include Coivolma pre-filled syringes (PFS) in 45 mg and 90 mg, as well as a 130 mg vial, Stoboclo PFS in 60 mg, and Osenbelt in a 120 mg vial. Coivolma is marketed globally under the name 'Stelara,' but a different brand name is used in Brazil to accommodate local language preferences.
Coivolma is a biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stoboclo and Osenbelt are biosimilars of denosumab, known as Prolia and Xgeva, respectively.
Celltrion plans to utilize its established network of hospitals and healthcare professionals to expand prescriptions for the new products. The strategy focuses on increasing product awareness and enhancing sales and marketing efforts in hospitals and clinics that have previously used Celltrion products.
The company also highlighted the market performance of its existing products as a foundation for the new launches. According to Celltrion, its autoimmune disease treatment 'Remsima' (infliximab) holds approximately 50% market share in Brazil's private sector. The breast cancer and stomach cancer treatment 'Herzuma' (trastuzumab) and the blood cancer treatment 'Truxima' (rituximab) have secured around 40% and 30% market shares, respectively.
With this launch, Celltrion's total product offerings in Brazil have increased to ten. In the autoimmune disease sector, the addition of the ustekinumab product expands its treatment options alongside existing infliximab, adalimumab, and omalizumab products.
The company is also preparing for subsequent launches. Celltrion is working towards the year-end release of the ophthalmic disease treatment 'Idenzelt' (aflibercept) and the autoimmune disease treatment 'Aptozumab' (tocilizumab), which will mark its expansion into the ophthalmic sector in Brazil.
A Celltrion representative stated, "We will leverage the customer network and trust built through our existing products to promote the early market entry and prescription expansion of new products, while continuing to launch subsequent products to enhance growth in Brazil and the broader Latin American market."
On November 5, Celltrion announced that its Brazilian subsidiary released the autoimmune disease treatment 'Coivolma' (active ingredient: ustekinumab) and the bone disease treatment 'Stoboclo' and 'Osenbelt' (active ingredient: denosumab) last month.
The newly launched products include Coivolma pre-filled syringes (PFS) in 45 mg and 90 mg, as well as a 130 mg vial, Stoboclo PFS in 60 mg, and Osenbelt in a 120 mg vial. Coivolma is marketed globally under the name 'Stelara,' but a different brand name is used in Brazil to accommodate local language preferences.
Coivolma is a biosimilar of ustekinumab used for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stoboclo and Osenbelt are biosimilars of denosumab, known as Prolia and Xgeva, respectively.
Celltrion plans to utilize its established network of hospitals and healthcare professionals to expand prescriptions for the new products. The strategy focuses on increasing product awareness and enhancing sales and marketing efforts in hospitals and clinics that have previously used Celltrion products.
The company also highlighted the market performance of its existing products as a foundation for the new launches. According to Celltrion, its autoimmune disease treatment 'Remsima' (infliximab) holds approximately 50% market share in Brazil's private sector. The breast cancer and stomach cancer treatment 'Herzuma' (trastuzumab) and the blood cancer treatment 'Truxima' (rituximab) have secured around 40% and 30% market shares, respectively.
With this launch, Celltrion's total product offerings in Brazil have increased to ten. In the autoimmune disease sector, the addition of the ustekinumab product expands its treatment options alongside existing infliximab, adalimumab, and omalizumab products.
The company is also preparing for subsequent launches. Celltrion is working towards the year-end release of the ophthalmic disease treatment 'Idenzelt' (aflibercept) and the autoimmune disease treatment 'Aptozumab' (tocilizumab), which will mark its expansion into the ophthalmic sector in Brazil.
A Celltrion representative stated, "We will leverage the customer network and trust built through our existing products to promote the early market entry and prescription expansion of new products, while continuing to launch subsequent products to enhance growth in Brazil and the broader Latin American market."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.